Pharmaceutical & Biotech
News and Insights
2015 Will Bring Changes for J&J Pension Benefits
In an effort to cut costs, J&J has announced that starting January 1, 2015 the company will reduce the pension benefits it offers to newly ...
Release of generic form of Nexium is delayed
With sales of AstraZeneca's Nexium bringing in over $2 billion in US sales last year, there are several generics makers who are ready to enter ...
Questions about Biosimilars
Recent inquires to the FDA have raised more questions about whether biosimilars should keep the same name as the branded biotech drugs. Doctor's state if ...
Plans for a Future Biotech Hub in New York
Pfizer, Eli Lilly and J&J have each contributed to a $51 million fund which will lay the groundwork the creation of a biotech hub on ...
High Price for Gilead’s Hepatitis C Treatment
Gilead's new hepatitis C treatment Savaldi came on the market in December. At that time, patients were receiving approval for the $84,000 treatment. Fast forward ...
Projected Top 10 Brands in 2020
With over $76 billion dollars in sales, 2013 was a good year for the best-selling drugs. According to EvaluatePharms'a annual world preview report, the top ...
AbbVie Continues its Quest for Shire
After three failed attempts, AbbVie has put together a $51.5 billion dollar deal to acquire Shire. AbbVie would like to expand on its top selling ...
Cubist Receives FDA Approval
Cubist has received FDA approval for Sivextro, an antibacterial drug it acquired after buying Trius about a year ago. This drug can be used to ...
Chicago to sue 5 Big Pharma Companies
Civil conspiracy and fraud are listed in a complaint that has been filed by the city of Chicago against five big pharma companies. This follows a ...
Possible Treatment for Type 2 Diabetes
Canadian researchers have found a naturally occurring molecule that could be used to treat individuals with insulin resistance and Type 2 diabetes. The molecule, called ...
- page 1 of 2 -